{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T23:33:15Z","timestamp":1675035195375},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,6,5]],"date-time":"2011-06-05T00:00:00Z","timestamp":1307232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00296-011-1972-1","type":"journal-article","created":{"date-parts":[[2011,6,4]],"date-time":"2011-06-04T10:35:11Z","timestamp":1307183711000},"page":"2349-2353","source":"Crossref","is-referenced-by-count":2,"title":["The relationship between plasma homocysteine level and different treatment modalities in patients with ankylosing spondylitis"],"prefix":"10.1007","volume":"32","author":[{"given":"Erhan","family":"Capkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Karkucak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Aky\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysegul Kucukali","family":"Turkyilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,5]]},"reference":[{"key":"1972_CR1","first-page":"969","volume-title":"Textbook of rheumatology","author":"S Linden Van der","year":"1997","unstructured":"Van der Linden S (1997) Ankylosing spondylitis. In: Kelley N, Ruddy S, Haris E, Sledge C (eds) Textbook of rheumatology. WB Saunders Company, Philadelphia, pp 969\u2013982"},{"key":"1972_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/096382899298007","volume":"21","author":"M Danyan","year":"1999","unstructured":"Danyan M, Guner A, Tuncer S et al (1999) Disability in ankylosing spondylitis. Disabil Rehabil 21:74\u201379","journal-title":"Disabil Rehabil"},{"key":"1972_CR3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/ard.59.12.985","volume":"59","author":"J Braun","year":"2000","unstructured":"Braun J, Khan MA, Sieper J (2000) Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 59:985\u2013994","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1972_CR4","first-page":"175","volume":"31","author":"\u015e Aksoy","year":"2006","unstructured":"Aksoy \u015e, Geyikli \u0130, Sayg\u0131l\u0131 E (2006) Determinants of plasma homocysteine levels in healthy people. Turk J Biochem 31(4):175\u2013181","journal-title":"Turk J Biochem"},{"key":"1972_CR5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/hrt.76.2.101","volume":"76","author":"G Montalescot","year":"1996","unstructured":"Montalescot G (1996) Homocysteine: the new player in the field of coronary risk. Heart 76:101\u2013102","journal-title":"Heart"},{"key":"1972_CR6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.1997.03540460039030","volume":"277","author":"I Graham","year":"1997","unstructured":"Graham I, Daly L, Refsum H et al (1997) Plasma homocysteine as a risk factor for vascular disease. JAMA 277:1775\u20131781","journal-title":"JAMA"},{"key":"1972_CR7","first-page":"1607","volume":"56","author":"P Fallest-Strobl","year":"1997","unstructured":"Fallest-Strobl P, Koch D, Stein J et al (1997) Ho-mocysteine: a new risk factor for atherosclerosis. Am Fam Phys 56:1607\u20131610","journal-title":"Am Fam Phys"},{"key":"1972_CR8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.STR.15.6.1012","volume":"15","author":"L Brattstrom","year":"1984","unstructured":"Brattstrom L, Hardebp E, Hultberg B (1984) Moderate homocysteinemia a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 15:1012\u20131016","journal-title":"Stroke"},{"key":"1972_CR9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0741-5214(91)90020-U","volume":"13","author":"L Taylor","year":"1991","unstructured":"Taylor L, De Frang R, Harris E et al (1991) The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13:128\u2013136","journal-title":"J Vasc Surg"},{"key":"1972_CR10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10067-006-0396-x","volume":"26","author":"J Wei","year":"2007","unstructured":"Wei J, Ming-Shiou J, Chen-Tung Y et al (2007) Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 26:739\u2013742","journal-title":"Clin Rheumatol"},{"key":"1972_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg H, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"1972_CR12","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy L et al (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"1972_CR13","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath as metrology index. J Rheumatol 21:1694\u20131698","journal-title":"J Rheumatol"},{"key":"1972_CR14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J et al (2003) ASAS working group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817\u2013824","journal-title":"Ann Rheum Dis"},{"key":"1972_CR15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ajcn\/73.3.613","volume":"73","author":"P Jacques","year":"2001","unstructured":"Jacques P, Bostom A, Wilson P et al (2001) Determinants of plasma total homocysteine concentrations in the Framingham offspring cohort. Am J Clin Nutr 73:613\u2013621","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"1972_CR16","first-page":"2374","volume":"31","author":"N Hornung","year":"2004","unstructured":"Hornung N, Ellingsen T, Stengaard-Pedersen K et al (2004) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 31(12):2374\u20132381","journal-title":"J Rheumatol"},{"issue":"2","key":"1972_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS20040326","volume":"109","author":"H Divecha","year":"2005","unstructured":"Divecha H, Sattar N, Rumley A et al (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109(2):171\u2013176","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"1972_CR18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/BOR.0b013e328133f58e","volume":"19","author":"S Heeneman","year":"2007","unstructured":"Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19(4):358\u2013362","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"1972_CR19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","volume":"5","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Kerekes G, Solt\u00e9sz P (2009) Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 5(12):677\u2013684","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-1972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-011-1972-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-1972-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T08:07:38Z","timestamp":1560240458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-011-1972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,5]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-1972-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,5]]}}}